567 related articles for article (PubMed ID: 27030023)
1. Cross-species analysis of Fc engineered anti-Lewis-Y human IgG1 variants in human neonatal receptor transgenic mice reveal importance of S254 and Y436 in binding human neonatal Fc receptor.
Burvenich IJ; Farrugia W; Lee FT; Catimel B; Liu Z; Makris D; Cao D; O'Keefe GJ; Brechbiel MW; King D; Spirkoska V; Allan LC; Ramsland PA; Scott AM
MAbs; 2016; 8(4):775-86. PubMed ID: 27030023
[TBL] [Abstract][Full Text] [Related]
2. Global conformational changes in IgG-Fc upon mutation of the FcRn-binding site are not associated with altered antibody-dependent effector functions.
Burvenich IJG; Farrugia W; Liu Z; Makris D; King D; Gloria B; Perani A; Allan LC; Scott AM; Ramsland PA
Biochem J; 2018 Jul; 475(13):2179-2190. PubMed ID: 29794155
[TBL] [Abstract][Full Text] [Related]
3. The neonatal Fc receptor (FcRn) binds independently to both sites of the IgG homodimer with identical affinity.
Abdiche YN; Yeung YA; Chaparro-Riggers J; Barman I; Strop P; Chin SM; Pham A; Bolton G; McDonough D; Lindquist K; Pons J; Rajpal A
MAbs; 2015; 7(2):331-43. PubMed ID: 25658443
[TBL] [Abstract][Full Text] [Related]
4. Fc Engineering of Human IgG1 for Altered Binding to the Neonatal Fc Receptor Affects Fc Effector Functions.
Grevys A; Bern M; Foss S; Bratlie DB; Moen A; Gunnarsen KS; Aase A; Michaelsen TE; Sandlie I; Andersen JT
J Immunol; 2015 Jun; 194(11):5497-508. PubMed ID: 25904551
[TBL] [Abstract][Full Text] [Related]
5. Anti-carcinoembryonic antigen single-chain variable fragment antibody variants bind mouse and human neonatal Fc receptor with different affinities that reveal distinct cross-species differences in serum half-life.
Andersen JT; Foss S; Kenanova VE; Olafsen T; Leikfoss IS; Roopenian DC; Wu AM; Sandlie I
J Biol Chem; 2012 Jun; 287(27):22927-37. PubMed ID: 22570488
[TBL] [Abstract][Full Text] [Related]
6. Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics.
Schoch A; Kettenberger H; Mundigl O; Winter G; Engert J; Heinrich J; Emrich T
Proc Natl Acad Sci U S A; 2015 May; 112(19):5997-6002. PubMed ID: 25918417
[TBL] [Abstract][Full Text] [Related]
7. Combined glyco- and protein-Fc engineering simultaneously enhance cytotoxicity and half-life of a therapeutic antibody.
Monnet C; Jorieux S; Souyris N; Zaki O; Jacquet A; Fournier N; Crozet F; de Romeuf C; Bouayadi K; Urbain R; Behrens CK; Mondon P; Fontayne A
MAbs; 2014; 6(2):422-36. PubMed ID: 24492301
[TBL] [Abstract][Full Text] [Related]
8. Identification of human IgG1 variant with enhanced FcRn binding and without increased binding to rheumatoid factor autoantibody.
Maeda A; Iwayanagi Y; Haraya K; Tachibana T; Nakamura G; Nambu T; Esaki K; Hattori K; Igawa T
MAbs; 2017 Jul; 9(5):844-853. PubMed ID: 28387635
[TBL] [Abstract][Full Text] [Related]
9. A novel in vitro assay to predict neonatal Fc receptor-mediated human IgG half-life.
Souders CA; Nelson SC; Wang Y; Crowley AR; Klempner MS; Thomas W
MAbs; 2015; 7(5):912-21. PubMed ID: 26018774
[TBL] [Abstract][Full Text] [Related]
10. Analytical FcRn affinity chromatography for functional characterization of monoclonal antibodies.
Schlothauer T; Rueger P; Stracke JO; Hertenberger H; Fingas F; Kling L; Emrich T; Drabner G; Seeber S; Auer J; Koch S; Papadimitriou A
MAbs; 2013; 5(4):576-86. PubMed ID: 23765230
[TBL] [Abstract][Full Text] [Related]
11. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
12. Changes in complementarity-determining regions significantly alter IgG binding to the neonatal Fc receptor (FcRn) and pharmacokinetics.
Piche-Nicholas NM; Avery LB; King AC; Kavosi M; Wang M; O'Hara DM; Tchistiakova L; Katragadda M
MAbs; 2018 Jan; 10(1):81-94. PubMed ID: 28991504
[TBL] [Abstract][Full Text] [Related]
13. An engineered human IgG1 antibody with longer serum half-life.
Hinton PR; Xiong JM; Johlfs MG; Tang MT; Keller S; Tsurushita N
J Immunol; 2006 Jan; 176(1):346-56. PubMed ID: 16365427
[TBL] [Abstract][Full Text] [Related]
14. Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life.
Mackness BC; Jaworski JA; Boudanova E; Park A; Valente D; Mauriac C; Pasquier O; Schmidt T; Kabiri M; Kandira A; Radošević K; Qiu H
MAbs; 2019 Oct; 11(7):1276-1288. PubMed ID: 31216930
[TBL] [Abstract][Full Text] [Related]
15. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
16. Development and applications of AlphaScreen-based FcRn binding assay to characterize monoclonal antibodies.
Wu Q; Lee HY; Wong PY; Jiang G; Gazzano-Santoro H
J Immunol Methods; 2015 May; 420():31-7. PubMed ID: 25837414
[TBL] [Abstract][Full Text] [Related]
17. Mapping the site on human IgG for binding of the MHC class I-related receptor, FcRn.
Kim JK; Firan M; Radu CG; Kim CH; Ghetie V; Ward ES
Eur J Immunol; 1999 Sep; 29(9):2819-25. PubMed ID: 10508256
[TBL] [Abstract][Full Text] [Related]
18. Engineering human IgG1 affinity to human neonatal Fc receptor: impact of affinity improvement on pharmacokinetics in primates.
Yeung YA; Leabman MK; Marvin JS; Qiu J; Adams CW; Lien S; Starovasnik MA; Lowman HB
J Immunol; 2009 Jun; 182(12):7663-71. PubMed ID: 19494290
[TBL] [Abstract][Full Text] [Related]
19. Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.
Ying T; Chen W; Feng Y; Wang Y; Gong R; Dimitrov DS
J Biol Chem; 2013 Aug; 288(35):25154-25164. PubMed ID: 23867459
[TBL] [Abstract][Full Text] [Related]
20. Altering Antibody-Drug Conjugate Binding to the Neonatal Fc Receptor Impacts Efficacy and Tolerability.
Hamblett KJ; Le T; Rock BM; Rock DA; Siu S; Huard JN; Conner KP; Milburn RR; O'Neill JW; Tometsko ME; Fanslow WC
Mol Pharm; 2016 Jul; 13(7):2387-96. PubMed ID: 27248573
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]